Search

Your search keyword '"Kannan, Srinivasaraghavan"' showing total 333 results

Search Constraints

Start Over You searched for: Author "Kannan, Srinivasaraghavan" Remove constraint Author: "Kannan, Srinivasaraghavan"
333 results on '"Kannan, Srinivasaraghavan"'

Search Results

1. PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression

2. Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists

4. Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities

5. CAMK2D serves as a molecular scaffold for RNF8-MAD2 complex to induce mitotic checkpoint in glioma

6. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

7. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

8. Modulation of Ideonella sakaiensis PETase active site flexibility and activity on morphologically distinct substrates by surface charge engineering

9. List of contributors

18. Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges

20. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation

21. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

22. Molecular descriptors suggest stapling as a strategy for optimizing membrane permeability of cyclic peptides.

23. Mechanisms of biased agonism by Gαi/o-biased stapled peptide agonists of the relaxin-3 receptor.

24. A high‐throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell‐based assays

25. Data from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

26. Supplementary Figures from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

27. Supplementary Tables from TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

28. Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonists

31. Design-Rules for Stapled Alpha-Helical Peptides with On-Target In Vivo Activity: Application to Mdm2/X dual antagonists

35. Discovery of novel interacting partners of PSMD9, a proteasomal chaperone: Role of an Atypical and versatile PDZ-domain motif interaction and identification of putative functional modules

37. Abstract 5239: Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation

38. Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology

39. Macrocyclization of an all-d linear α-helical peptide imparts cellular permeability† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc06383h

46. Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling

47. A chemical biology approach reveals a dependency of glioblastoma on biotin distribution

48. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.

Catalog

Books, media, physical & digital resources